Growing crystals acceptable for single crystal x-ray diffraction (SCXRD) structure determination is challenging and requires patience, intuition, and care. Our researchers have a high level of expertise in single crystal growth techniques and the physical and chemical properties of the material are examined to determine the best crystallization techniques.

 

Our methods include:

   • Slow evaporation
   • Slow cooling
   • Vapor diffusion
   • Liquid diffusion
   • Sitting/hanging drop
   • Sublimation
   • Co-crystallants

Crystal Pharmatech is the first technology-driven, China based contract research organization (CRO) that focuses on materials science and engineering for drug development. We partner with clients to ensure comprehensive solutions for their needs in solid-state research, crystallization process development, and preformulation studies. We guide clients in the discovery and selection of the optimal solid phase for drug development using all aspects of pre-formulation studies, including API process and formulation development, regulatory support and intellectual property protection.

Founded in 2010, Crystal Pharmatech has business relationships with over 60 global pharmaceutical companies. High quality service, a culture of confidentiality, and fast turnaround with cost-effective pricing are our trademarks. As we continue to grow, Crystal Pharmatech will always keep customers our number one priority. We will also continue to be at the forefront of innovation in the field of solid-state chemistry so that our customers can reap the benefits of key discoveries in an ever changing field.

Our Scientific Advisory Board includes global leaders in drug development covering amorphous dispersions, co-crystals, crystallization, solid forms, formulation and pre-formulation. The role of our board is all encompassing while we search for new scientific areas for internal and external projects.